# Phase IV Study of Qsymia in Obese Patients

> **NCT05378503** · PHASE4 · COMPLETED · sponsor: **Alvogen Korea** · enrollment: 232 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** Qsymia 3.75Mg-23Mg Extended Release Capsule
- **DRUG:** Qsymia 7.5Mg-46Mg Extended Release Capsule
- **DRUG:** Qsymia 11.25Mg-69Mg Extended Release Capsule
- **DRUG:** Qsymia 15Mg-92Mg Extended Release Capsule
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05378503
- **Lead sponsor:** Alvogen Korea
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-17
- **Primary completion:** 2023-10-30
- **Final completion:** 2023-10-30
- **Target enrollment:** 232 (ACTUAL)
- **Last updated:** 2024-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05378503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05378503, "Phase IV Study of Qsymia in Obese Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05378503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*